Longevity & MitochondrialPreclinical / anecdotal

EDR (Glu-Asp-Arg)

Pinealon, Tripeptide bioregulator

A short chain tripeptide bioregulator (Glu-Asp-Arg) from the Khavinson program, studied for neuroprotection and a proposed, but under validated, direct gene promoter binding mechanism.

Neuroprotection Cognition Sleep

Glu-Asp-Arg

Sequence

Neural cells

Tissue focus

Human RCTs

Mechanism of action

How Pinealon works

An ultrashort tripeptide bioregulator studied for protecting neurons, with a striking, under validated claim that it binds DNA directly to tune gene expression.

Pinealon

EDR tripeptide

Cell + nucleus

Membrane penetrant

Gene promoters

Proposed binding

Neuroprotection

↓ ROS

Also studied

In vitro, reduces reactive oxygen species and necrotic death in cerebellar granule cells, neutrophils, and PC12 cells.

See related compounds

The most cited and least clinically validated claim: the ultrashort peptide is proposed to bind gene promoters directly (CASP3, APOE, SOD2).

See related compounds

Marketed for circadian and sleep support, but no completed peer reviewed human RCTs exist.

See related compounds

Applications

Research applications

Neuroprotection

Oxidative stress reduction

In vitro / cell model

Neural cell models

Cognition / TBI

Memory support

Human pilot data

Russian observational

Circadian / sleep

Marketed claim

Animal (rodent) model

No human RCT

Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.

Compound data

Molecular profile

CAS number175175-23-2

Molecular formulaC15H26N6O8

Molecular weight418.40 g/mol

TypeTripeptide bioregulator

SequenceGlu-Asp-Arg (EDR)

AppearanceWhite lyophilized powder

Full profile

Evidence, safety & status

Claimed benefits & evidence

Marketed for neuroprotection, cognition, and circadian/sleep support. Carries the same single network limitation as Epitalon and BPC-157, essentially all evidence is from Khavinson's group. PubMed returns no completed peer reviewed RCTs; a Russian observational TBI study and rodent learning data exist. The DNA promoter binding mechanism is the most cited and least clinically validated part of the story.

Safety & dangers

No significant adverse effects in the thin (mostly preclinical/Russian) literature, but human safety is effectively uncharacterized, no PK, toxicology, or long term data. Theoretical concern of unknown off target gene effects.

Contraindications

Pregnancy; active malignancy (theoretical); anyone unable to verify product quality.

Regulatory status

Not FDA approved; research use only / gray market. Often paired commercially with Epitalon as a 'Russian longevity stack.' WADA: S0.

Administration

Subcutaneous or intranasal, short courses. Oral bioavailability is very poor.

Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. Anyone considering these compounds should consult a qualified physician.

For research use only

For Research Use Only. Not for human or animal consumption. Products are sold strictly for in vitro laboratory research, not for compounding or therapeutic application.